Biotech Values

[DewDiligence]

NVS’ Tasigna receives FDA priority review in first-line CML:

http://finance.yahoo.com/news/Novartis-Drug-TasignaR-prnews-1439979667.html?x=0&.v=1

Tasigna is already approved in all major jurisdictions for second-line CML following Gleevec, but the first-line setting (along with non-CML indications) is where the big money is. Worldwide, Gleevec outsells Tasigna and Sprycel combined by about 6:1 ($4.3B vs [$260M+$480M] annualized 4Q09 run rates).